HOUSTON, April 20 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals today announced that the Company will be presenting a corporate overview at three upcoming health care conferences: the UBS Global Specialty Pharmaceuticals Conference, Deutsche Bank 31st Annual Health Care Conference, and Rodman & Renshaw 3rd Annual Global Healthcare Conference.
Encysive Pharmaceuticals' presentation schedule is as follows: * UBS Global Specialty Pharmaceuticals Conference - April 24th at 3 p.m. EDT at the Grand Hyatt Hotel in New York City * Deutsche Bank 31st Annual Health Care Conference - May 2nd at 4 p.m. EDT at the Sheraton Hotel in Boston * Rodman & Renshaw 3rd Annual Global Healthcare Conference - May 15th at 1 p.m. CEST (7 a.m. EDT) at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco
A live webcast of each presentation may be viewed on the Company's web site at http://www.encysive.com . A replay will be available for 30 days following each respective presentation.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com .
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are our estimate of the sufficiency of our existing capital resources, our ability to raise additional capital to fund cash requirements for future operations, timelines for initiating new clinical trials, planned announcements of clinical data, the possibility of obtaining regulatory approval, our ability to manufacture and sell any products, potential drug candidates, their potential therapeutic effect, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate, our ability to discover new drugs in the future, and our ability to establish future collaborative arrangements, as well as more specific risks, trends and uncertainties facing Encysive such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward looking statements may prove to be incorrect. Therefore you should not rely on any such forward looking statements. Furthermore, Encysive undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Encysive Pharmaceuticals Inc.CONTACT: investors, Ann Tanabe of Encysive Pharmaceuticals Inc.,+1-713-796-8822; or Marcy Strickler of The Trout Group, +1-212-477-9007ext. 27; or media, Dan Budwick of BMC Communications, +1-212-477-9007, ext.14, both for Encysive Pharmaceuticals Inc.
Web site: http://www.encysive.com/
